GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

volagidemab   Click here for help

GtoPdb Ligand ID: 14320

Synonyms: AMG-477 | AMG477 | REMD-477 | REMD477
Compound class: Antibody
Comment: Volagidemab (REMD-477) is a fully human anti-glucagon receptor monoclonal antibody. It acts as an antagonist of receptor function.
Based on peptide sequence matches for antibody heavy and light chains between the INN record and patent US7947809B2, volagidemab appears to be clone A-4 therein [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Volagidemab (REMD-477) was progressed to clinical evaluations to determine safety and efficacy as a therapy for type 1 and type 2 diabetes.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02455011 Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus Phase 1/Phase 2 Interventional REMD Biotherapeutics, Inc.
NCT02715193 Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus Phase 1 Interventional REMD Biotherapeutics, Inc. 2
NCT03117998 Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus Phase 2 Interventional REMD Biotherapeutics, Inc. 1